There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Background Natalizumab is a humanized monoclonal antibody used for treatment of highly
active relapsing-remitting multiple sclerosis (MS). With more than 15 years of post-marketing …

The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-
modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding …

JC polyomavirus (JCV) establishes an asymptomatic latent and/or persistent infection in
most of the adult population. However, in immunocompromised individuals, JCV can cause …

Despite advances in the treatment of chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP) and other common autoimmune neuropathies (AN), still …

Gut-tropic T cells primarily originate from gut-associated lymphoid tissue (GALT), and gut-
tropic integrins mediate the trafficking of the T cells to the gastrointestinal tract, where their …

Background: Accumulating evidence supports the efficacy of administering natalizumab (NZ)
with extended-interval dosing (EID) in patients with relapsing-remitting multiple sclerosis …

With a rapidly aging global population and improvement of outcomes with newer multiple
sclerosis (MS)-specific disease-modifying therapies (DMTs), the epidemiology of MS has …

Introduction Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous
system. Monoclonal antibodies (mAbs) have shown efficacy in reducing MS relapse rates …

Almost all currently licensed disease-modifying therapies (DMTs) for MS treatment require
prolonged if not lifelong administration. Yet, as people age, the immune system has …